Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation

J R Schriber(Arizona Oncology), GP Herzig(Roswell Park Comprehensive Cancer Center), Neal P. Christiansen(University of Minnesota), B Milk(Roswell Park Comprehensive Cancer Center), James L. Slack(Memorial Sloan Kettering Cancer Center), H. Tezcan(Roswell Park Comprehensive Cancer Center), Meir Wetzler, Darcy H. Shaw(Roswell Park Comprehensive Cancer Center), Maria R. Baer(University of Maryland, Baltimore)
Bone Marrow Transplantation
December 1, 1999
10.1038/sj.bmt.1702069
Cited by 32

Related Papers

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493